skip to main content

KATHERINE T-DM1 — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateBreast CancerKATHERINE T-DM1SCE Medical Oncology

A 55-year-old woman with HER2-positive breast cancer has T-DM1 adjuvant therapy after non-pCR to neoadjuvant anti-HER2 + chemotherapy. What trial established this approach?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — KATHERINE — T-DM1 reduced invasive disease recurrence by 50% compared with trastuzumab alone in patients with residual invasive disease after neoadjuvant anti-HER2 + chemotherapy

KATHERINE (von Minckwitz et al NEJM 2019): patients with residual invasive disease after neoadjuvant trastuzumab+chemo randomised to 14 cycles adjuvant T-DM1 vs trastuzumab. iDFS: 88.3% vs 77.0% (HR 0.50). This established T-DM1 as standard for non-pCR HER2+ disease.

Reference: NICE TA632; KATHERINE von Minckwitz et al NEJM 2019